Stock Detail
$PFE
Healthcare · 9 tracked mentions in the last 90 days across 7 creators.
Valuation and creator stance reflect the last 90 days. The mention feed below shows the latest tracked mentions across all history.
PFE leans undervalued across 3 creators and 6 classified valuation claims, with 3 direct claims carrying most of the signal.
Creator Evidence
Why creators say this
Explicit claim • strong conviction • basis: multiple relative
EPS projected per se Alpha $2.98. That brings a price to earnings ratio at under 10 at 9.33.
Explicit claim • strong conviction • basis: explicit term
And at the exact same time, they're trading at what looks like a dirt cheap valuation. The average PE multiple over the last 3 years for them is about 10.7. Now, they're all the way down to just 8.7 times earnings.
Explicit claim • strong conviction • basis: market mispricing
So when you step back and look at the big picture, Pfizer is not a short-term trade. It is a long-term compounding machine that is currently being priced as if its best days are behind it.
Explicit claim • strong conviction • basis: fair value gap
Pfizer (PFE) is a buy, presenting deep value with a dirt-cheap valuation, a high dividend yield, and strategic acquisitions in key growth areas.
Mention History
Latest mentions across all history
Feed